Allergan and Ironwood Pharmaceuticals agreed to a settlement with Sun Pharma to resolve a patent dispute over the Indian company's abbreviated new drug application for a generic version of Linzess (linaclotide) in the U.S. The settlement, which will be subject to review by the U.S. Department of Justice and the Federal Trade Commission, will allow wholly-owned subsidiaries of Sun Pharma to seek a license to launch a generic version of Linzess in the U.S. beginning Feb. 1, 2031 -- or earlier, in certain circumstances -- and end the patent infringement litigation.